Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Italy Porcine Vaccines Market

ID: MRFR/Pharma/48723-HCR
200 Pages
Vikita Thakur
March 2026

Italy Porcine Vaccines Market Research Report By Type (Inactivated vaccines, Live attenuated vaccines, Toxoid vaccines, Recombinant vaccines, Conjugate vaccines, DNA vaccines), By Disease Indication (PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), Swine influenza, Aujeszky's disease (AD), Porcine Circovirus Associated Disease (PCVAD), Others) and By End-user (Veterinary Hospitals, Hog Production Farm) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Italy Porcine Vaccines Market Infographic
Purchase Options

Italy Porcine Vaccines Market Summary

As per Market Research Future analysis, the Italy porcine vaccines market size was estimated at 67.2 USD Million. in 2024. The Italy porcine vaccines market is projected to grow from 70.84 USD Million in 2025 to 120.0 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 5.4% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Italy porcine vaccines market is experiencing a robust shift towards enhanced disease prevention and technological innovation.

  • The market is characterized by an increased focus on disease prevention, reflecting a broader trend in animal health management.
  • Technological advancements in vaccine formulations are driving efficiency and effectiveness in disease control among swine populations.
  • Regulatory support for vaccination practices is strengthening, facilitating wider adoption of innovative vaccine solutions.
  • Rising demand for sustainable farming practices and increased awareness of animal health are key drivers propelling market growth.

Market Size & Forecast

2024 Market Size 67.2 (USD Million)
2035 Market Size 120.0 (USD Million)
CAGR (2025 - 2035) 5.41%

Major Players

Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Ceva Santé Animale (FR), Virbac (FR), Heska Corporation (US), Vetoquinol (FR)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Italy Porcine Vaccines Market Trends

The porcine vaccines market is currently experiencing notable developments. This growth is driven by the increasing demand for effective disease management in swine populations. This demand is largely influenced by the rising awareness of animal health and welfare among farmers and consumers alike. In Italy, the focus on biosecurity measures and vaccination protocols has intensified, as producers seek to mitigate the risks associated with diseases such as Porcine Reproductive and Respiratory Syndrome (PRRS) and Swine Influenza. The regulatory environment is also evolving, with authorities emphasizing the importance of vaccination in maintaining herd health and productivity. Moreover, advancements in vaccine technology are contributing to the growth of the porcine vaccines market. Innovative approaches, such as the development of recombinant vaccines and improved adjuvants, are enhancing the efficacy and safety profiles of available products. This trend is likely to encourage more producers to adopt vaccination as a standard practice in their operations. As the market continues to evolve, collaboration between veterinary professionals, researchers, and producers will be crucial in addressing emerging challenges and ensuring the sustainability of swine production in Italy.

Increased Focus on Disease Prevention

The porcine vaccines market is witnessing a heightened emphasis on disease prevention strategies. Producers are increasingly recognizing the economic impact of diseases on swine health and productivity. This awareness is driving investments in vaccination programs, as farmers aim to protect their herds from prevalent infections.

Technological Advancements in Vaccines

Recent innovations in vaccine development are shaping the porcine vaccines market. The introduction of novel vaccine formulations and delivery methods is enhancing the effectiveness of immunization. These advancements are likely to improve the overall health of swine populations and reduce the incidence of disease outbreaks.

Regulatory Support for Vaccination Practices

The regulatory landscape is evolving to support vaccination practices within the porcine vaccines market. Authorities are implementing guidelines that promote the use of vaccines as a critical component of herd management. This regulatory backing is expected to foster greater adoption of vaccination among producers.

Italy Porcine Vaccines Market Drivers

Emerging Infectious Diseases

New infectious diseases pose a substantial challenge to the porcine vaccines market in Italy. As pathogens evolve, the need for innovative vaccines becomes increasingly critical. The Italian agricultural sector is currently facing threats from diseases such as African Swine Fever (ASF), which necessitates the development of effective vaccination strategies. This urgency may drive research and development efforts, potentially leading to a surge in vaccine offerings. Consequently, the porcine vaccines market could see a significant uptick in demand, with projections indicating a growth rate of 8% as the industry responds to these emerging health threats.

Expansion of Veterinary Services

The expansion of veterinary services in Italy is playing a crucial role in the growth of the porcine vaccines market. With an increasing number of veterinary clinics and mobile veterinary services, farmers now have better access to vaccination programs and veterinary advice. This accessibility is likely to enhance vaccination coverage among pig populations, which could lead to a reduction in disease outbreaks. As a result, the porcine vaccines market may experience a compound annual growth rate (CAGR) of approximately 4% as more farmers engage with veterinary professionals to implement vaccination strategies.

Government Initiatives and Funding

Government initiatives aimed at improving livestock health are significantly influencing the porcine vaccines market in Italy. Financial support and subsidies for vaccination programs are being provided to farmers, encouraging them to invest in preventive health measures. These initiatives are designed to enhance biosecurity and reduce the economic burden of disease outbreaks. As a result, the porcine vaccines market is likely to benefit from increased funding, potentially leading to a market growth of 7% as farmers take advantage of these government programs to protect their herds.

Increased Awareness of Animal Health

There is a growing awareness of animal health among Italian farmers, which is significantly impacting the porcine vaccines market. Educational initiatives and outreach programs have been implemented to inform farmers about the benefits of vaccination in preventing diseases such as Porcine Reproductive and Respiratory Syndrome (PRRS). This heightened awareness is likely to lead to increased vaccination rates, potentially resulting in a market growth of around 6% over the next few years. As farmers recognize the economic advantages of maintaining healthy herds, the demand for effective vaccines is expected to rise, thereby bolstering the porcine vaccines market.

Rising Demand for Sustainable Farming Practices

The porcine vaccines market in Italy is experiencing a significant shift towards sustainable farming practices. As consumers increasingly prioritize animal welfare and environmentally friendly production methods, farmers are compelled to adopt practices that minimize antibiotic use. This trend is likely to drive the demand for effective vaccines that can prevent diseases without relying on antibiotics. The Italian government has also been promoting sustainable agriculture, which may further encourage the adoption of vaccination programs. Consequently, the porcine vaccines market could see a growth rate of approximately 5% annually as farmers seek to comply with these evolving standards.

Market Segment Insights

By Type: Inactivated vaccines (Largest) vs. Live attenuated vaccines (Fastest-Growing)

The Italy porcine vaccines market is characterized by a diverse array of vaccines, with inactivated vaccines holding the largest share. These vaccines are widely accepted due to their established efficacy and safety profiles. Following closely are live attenuated vaccines, which have gained traction in recent years. Both of these vaccine types cater to the needs of swine producers looking for reliable immunization options. Growth trends indicate a shift towards live attenuated vaccines, propelled by their effectiveness in providing long-lasting immunity and their cost-effectiveness compared to inactivated options. Additionally, increasing awareness of porcine health, supported by advancements in vaccine production technology, fosters market expansion. This dynamic landscape allows emerging vaccine types to capture attention alongside established ones.

Inactivated vaccines (Dominant) vs. Live attenuated vaccines (Emerging)

Inactivated vaccines serve as the dominant vaccine type in the Italy porcine vaccines market, appreciated for their reliability in immunization against various diseases affecting swine. Their extensive testing ensures high safety margins, making them the preferred choice among many producers. Conversely, live attenuated vaccines represent an emerging segment due to their ability to elicit strong immune responses. They provide a promising alternative by significantly reducing disease incidence and facilitating herd immunity. Both vaccine types demonstrate unique advantages, with inactivated vaccines leading in market presence while live attenuated vaccines are rapidly gaining recognition for their effectiveness and economic viability.

By Disease Indication: PRRS (Largest) vs. PED (Fastest-Growing)

In the Italy porcine vaccines market, PRRS (Porcine Reproductive & Respiratory Syndrome) holds the largest market share among disease indications, exemplifying its critical importance in safeguarding swine health. Other segments like PED (Porcine Epidemic Diarrhea) and Swine influenza also contribute, but PRRS remains the focal point due to its widespread impact on pig populations across the country. Looking forward, the growth trends indicate a rise in demand for vaccines targeting PED, which is becoming the fastest-growing segment as outbreaks have heightened awareness and preventive measures among swine producers. Factors driving this growth include increased investments in biosecurity measures, rising awareness about the economic losses linked to these diseases, and a growing emphasis on improving herd immunity in swine herds.

PRRS (Dominant) vs. PED (Emerging)

PRRS is recognized as the dominant disease indication in the Italy porcine vaccines market, characterized by its significant impact on reproductive performance and respiratory health in pigs. Vaccines for PRRS are designed to mitigate the clinical signs and reduce transmission rates, contributing to healthier herds. Meanwhile, PED is emerging as a critical focus area due to its rapid spread and severe economic implications, making it vital for producers to adopt effective vaccination strategies. The increasing number of outbreaks has spurred vaccine development, highlighting the urgency in combating this disease. Each disease presents unique challenges, but both PRRS and PED are pivotal in shaping the current market dynamics, with PRRS leading now and PED on an explosive growth trajectory.

By End-user: Hog Production Farm (Largest) vs. Veterinary Hospitals (Fastest-Growing)

In the Italy porcine vaccines market, the Hog Production Farm segment holds a substantial share, dominating the overall market landscape due to the high demand for vaccine solutions aimed at enhancing swine health. This segment is critical as it comprises numerous large-scale producers focused on maximizing yields and minimizing disease outbreaks, thus occupying a significant portion of market share. On the other hand, Veterinary Hospitals are emerging as a crucial segment, reflecting a notable % share driven by the rising trend of specialized veterinary care, coupled with an increasing awareness of the importance of veterinary health practices among farmers. Growth trends in the Italy porcine vaccines market showcase a robust upward trajectory for both segments. Hog Production Farms are increasingly adopting advanced vaccine technologies to address various health challenges, thereby driving substantial market expansion. Meanwhile, Veterinary Hospitals are experiencing rapid growth as they enhance their service offerings and integrate advanced diagnostic tools, appealing to a broader range of clients seeking quality healthcare for their livestock. This trend is likely to continue as farmers prioritize health management and disease prevention, leading to increased investment in veterinary services and vaccines.

Hog Production Farm (Dominant) vs. Veterinary Hospitals (Emerging)

The Hog Production Farm segment stands out as the dominant player in the Italy porcine vaccines market due to its large operational scale and concentrated need for effective vaccine solutions. This segment is characterized by its focus on maximizing livestock productivity and minimizing disease spread, which necessitates the continual introduction of advanced vaccination strategies. In contrast, the Veterinary Hospitals segment is emerging, marked by a shift toward specialized veterinary services that enhance animal health management. These hospitals are expanding their capabilities to provide comprehensive care, including vaccination services, diagnostics, and treatment plans tailored for swine health. As a result, both segments play essential roles in the market, catering to the evolving needs of pork producers and reinforcing the importance of animal health management.

Get more detailed insights about Italy Porcine Vaccines Market

Key Players and Competitive Insights

The porcine vaccines market in Italy is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on sustainability. Key players such as Zoetis (US), Boehringer Ingelheim (DE), and Merck Animal Health (US) are actively pursuing strategies that emphasize research and development, aiming to introduce advanced vaccine formulations that address emerging health challenges in swine populations. This competitive environment is further influenced by the growing demand for high-quality animal health products, driven by both consumer preferences for sustainable farming practices and regulatory pressures aimed at reducing antibiotic use in livestock.In terms of business tactics, companies are localizing manufacturing processes and optimizing supply chains to enhance efficiency and responsiveness to market needs. The market structure appears moderately fragmented, with several players vying for market share while also collaborating on research initiatives. This collective influence of key players fosters a dynamic environment where innovation and operational excellence are paramount.

In October Boehringer Ingelheim (DE) announced the launch of a new vaccine targeting Porcine Reproductive and Respiratory Syndrome (PRRS), a significant advancement in the fight against this prevalent disease. This strategic move not only reinforces Boehringer's commitment to addressing critical health issues in swine but also positions the company as a leader in vaccine innovation, potentially increasing its market share in Italy.

In September Merck Animal Health (US) expanded its partnership with local Italian veterinary organizations to enhance the distribution of its vaccine portfolio. This collaboration is strategically important as it allows Merck to leverage local expertise and networks, thereby improving access to its products and fostering stronger relationships with veterinarians and farmers. Such initiatives are likely to enhance brand loyalty and market penetration.

In August Zoetis (US) unveiled a digital platform aimed at providing farmers with real-time data on vaccine efficacy and herd health management. This initiative reflects a broader trend towards digitalization in the animal health sector, suggesting that Zoetis is keen on integrating technology into its offerings to provide added value to its customers. The potential for data-driven decision-making in herd management could significantly influence purchasing behaviors in the market.

As of November current trends in the porcine vaccines market indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence in product development and customer engagement. Strategic alliances among companies are increasingly shaping the competitive landscape, fostering innovation and enhancing supply chain reliability. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on technological advancements, innovative solutions, and sustainable practices, thereby redefining the parameters of success in the market.

Key Companies in the Italy Porcine Vaccines Market include

Industry Developments

The Italy Porcine Vaccines Market has seen significant developments recently, particularly in relation to advancements in vaccine technologies and increased demand for efficient disease management among swine populations. Companies such as Zoetis, Ceva Santé Animale, and Boehringer Ingelheim are actively investing in Research and Development to improve vaccine efficacy, with new formulations being introduced to combat diseases like Porcine Reproductive and Respiratory Syndrome (PRRS) and Porcine Epidemic Diarrhea Virus (PEDV). In August 2023, Merck Animal Health announced an expansion in its vaccine production capacity in Italy, aligning with growing market needs. 

Furthermore, Hipra has focused on bolstering its position in the market, promoting its novel vaccines which have received positive feedback from veterinary professionals. No recent mergers or acquisitions have been publicly reported among key companies like Virbac and Heska Corporation in 2023, indicating a stable competitive landscape. The Italian government continues to support the livestock sector, enhancing regulatory frameworks that aim to promote animal health and welfare, further impacting the dynamics of the Porcine Vaccines Market positively. This market is projected to witness continued growth due to rising pork consumption and the necessity for effective vaccination strategies.

Future Outlook

Italy Porcine Vaccines Market Future Outlook

The Porcine Vaccines Market is projected to grow at a 5.41% CAGR from 2025 to 2035, driven by increasing disease outbreaks, advancements in vaccine technology, and rising demand for pork products.

New opportunities lie in:

  • Development of customized vaccine formulations for specific regional diseases.
  • Expansion of e-commerce platforms for vaccine distribution.
  • Investment in research for novel adjuvants to enhance vaccine efficacy.

By 2035, the porcine vaccines market is expected to achieve robust growth and innovation.

Market Segmentation

Italy Porcine Vaccines Market Type Outlook

  • Inactivated vaccines
  • Live attenuated vaccines
  • Toxoid vaccines
  • Recombinant vaccines
  • Conjugate vaccines
  • DNA vaccines

Italy Porcine Vaccines Market End-user Outlook

  • Veterinary Hospitals
  • Hog Production Farm

Italy Porcine Vaccines Market Disease Indication Outlook

  • PED (Porcine Epidemic Diarrhea)
  • PRRS (Porcine Reproductive & Respiratory Syndrome)
  • Swine influenza
  • Aujeszky's disease (AD)
  • Porcine Circovirus Associated Disease (PCVAD)
  • Others

Report Scope

MARKET SIZE 2024 67.2(USD Million)
MARKET SIZE 2025 70.84(USD Million)
MARKET SIZE 2035 120.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 5.41% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Ceva Santé Animale (FR), Virbac (FR), Heska Corporation (US), Vetoquinol (FR)
Segments Covered Type, Disease Indication, End-user
Key Market Opportunities Advancements in vaccine technology enhance disease prevention in the porcine vaccines market.
Key Market Dynamics Rising demand for innovative porcine vaccines driven by regulatory changes and evolving disease threats in Italy.
Countries Covered Italy
Author
Author
Author Profile
Vikita Thakur LinkedIn
Senior Research Analyst
She holds an experience of about 5+ years in market research and business consulting projects for sectors such as life sciences, medical devices, and healthcare IT. She possesses a robust background in data analysis, market estimation, competitive intelligence, pipeline analysis market trend identification, and consumer behavior insights. Her expertise lies in technical Sales support, client interaction and project management, designing and implementing market research studies, conducting competitive analysis, and synthesizing complex data into actionable recommendations that drive business growth.
Co-Author
Co-Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Leave a Comment

FAQs

What is the current valuation of the porcine vaccines market in Italy as of 2024?

<p>The market valuation was $67.2 Million in 2024.</p>

What is the projected market valuation for the Italy porcine vaccines market by 2035?

<p>The projected valuation for 2035 is $120.0 Million.</p>

What is the expected CAGR for the Italy porcine vaccines market during the forecast period 2025 - 2035?

<p>The expected CAGR during this period is 5.41%.</p>

Which companies are the key players in the Italy porcine vaccines market?

<p>Key players include Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco Animal Health, Ceva Santé Animale, Virbac, Heska Corporation, and Vetoquinol.</p>

What are the main types of vaccines available in the Italy porcine vaccines market?

<p>Main types include inactivated vaccines, live attenuated vaccines, toxoid vaccines, recombinant vaccines, conjugate vaccines, and DNA vaccines.</p>

What was the market value of live attenuated vaccines in 2024?

<p>The market value of live attenuated vaccines was between $20.0 Million and $35.0 Million.</p>

How does the market for porcine vaccines segment by disease indication?

<p>The market segments include PED, PRRS, swine influenza, Aujeszky's disease, PCVAD, and others.</p>

What was the market value for PRRS vaccines in 2024?

<p>The market value for PRRS vaccines ranged from $15.0 Million to $25.0 Million.</p>

Which end-users are primarily involved in the Italy porcine vaccines market?

<p>Primary end-users include veterinary hospitals and hog production farms.</p>

What was the market value for hog production farms in 2024?

<p>The market value for hog production farms was between $47.04 Million and $85.0 Million.</p>

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions